miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth

Marija Mihailovich, Michael Bremang, Valeria Spadotto, Daniele Musiani, Elena Vitale, Gabriele Varano, Federico Zambelli, Francesco M. Mancuso, David A. Cairns, Giulio Pavesi, Stefano Casola and Tiziana Bonaldi ()
Additional contact information
Marija Mihailovich: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Michael Bremang: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Valeria Spadotto: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Daniele Musiani: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Elena Vitale: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Gabriele Varano: Units of Genetics of B cells and lymphomas, IFOM, FIRC Institute of Molecular Oncology Foundation
Federico Zambelli: Milan University
Francesco M. Mancuso: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
David A. Cairns: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy
Giulio Pavesi: Milan University
Stefano Casola: Units of Genetics of B cells and lymphomas, IFOM, FIRC Institute of Molecular Oncology Foundation
Tiziana Bonaldi: European Institute of Oncology, Via Adamello 16, Milan 20139, Italy

Nature Communications, 2015, vol. 6, issue 1, 1-15

Abstract: Abstract The synergism between c-MYC and miR-17-19b, a truncated version of the miR-17-92 cluster, is well-documented during tumor initiation. However, little is known about miR-17-19b function in established cancers. Here we investigate the role of miR-17-19b in c-MYC-driven lymphomas by integrating SILAC-based quantitative proteomics, transcriptomics and 3′ untranslated region (UTR) analysis upon miR-17-19b overexpression. We identify over one hundred miR-17-19b targets, of which 40% are co-regulated by c-MYC. Downregulation of a new miR-17/20 target, checkpoint kinase 2 (Chek2), increases the recruitment of HuR to c-MYC transcripts, resulting in the inhibition of c-MYC translation and thus interfering with in vivo tumor growth. Hence, in established lymphomas, miR-17-19b fine-tunes c-MYC activity through a tight control of its function and expression, ultimately ensuring cancer cell homeostasis. Our data highlight the plasticity of miRNA function, reflecting changes in the mRNA landscape and 3′ UTR shortening at different stages of tumorigenesis.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms9725 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9725

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms9725

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().